🇺🇸

US SEC Filing Intelligence

· daily

Mega Contracts Monitor ($100M+) — April 18, 2026

Three civilian mega contracts totaling $4,108,202,635 were awarded across HHS, VA, and GSA, with zero defense-related obligations, highlighting robust demand in health administration, insurance, and engineering services. Dominant themes center on VA and HHS health/insurance programs alongside GSA engineering support, led by MAXIMUS FEDERAL SERVICES, INC.'s $2.78B HHS award as the highest materiality bullish signal at 8/10. CACI NSS, LLC's $399.6M GSA delivery order adds a high-conviction bullish signal (8/10 strength) for engineering services with potential extension to 2026. TRIWEST HEALTHCARE ALLIANCE CORP's $928.9M VA order remains neutral due to data anomalies including zero funds outlayed and post-performance award date. Key watch item: monitor TriWest funds outlay progress and CACI option exercises beyond June 29, 2023 amid negative outlays.

3 total filings
· daily

High-Value Federal Grants ($5M+) — April 18, 2026

High-value federal grants totaling $4,174,924,202 were awarded across four civilian contracts from April 18, 2026, with zero defense-related activity, highlighting pure civilian agency exposure in health services, engineering, and environmental remediation. Dominant themes center on Department of Health and Human Services (HHS) and Department of Veterans Affairs (VA) health/insurance programs, comprising over 90% of value via MAXIMUS FEDERAL SERVICES, INC. ($2.78B) and TRIWEST HEALTHCARE ALLIANCE CORP. ($929M). Highest-conviction bullish signal is CACI NSS, LLC's $399.6M GSA engineering delivery order (strength 8/10), supporting potential revenue of $80M/year through 2026. Key risk is execution anomalies, including TRIWEST's $0 outlay and post-performance award date, plus CACI's negative -$530K outlayed.

4 total filings
· daily

General Federal Contracts — April 18, 2026

These four civilian contracts total $4,174,924,202 in obligations with 0/4 defense-related, highlighting HHS and VA dominance in health services alongside GSA engineering and EPA remediation. MAXIMUS FEDERAL SERVICES, INC. leads with a massive $2.78B HHS award, while CACI NSS, LLC secured a bullish $399.6M GSA engineering delivery order. Highest-conviction signal is CACI's Cost Plus Award Fee structure with low pricing risk and potential extension to 2026. Key risk is data anomalies including TriWest's $928.9M VA award with future performance dates (March 2026) post-award (April 2026) and $0 outlay, plus CACI's negative -$530K outlay.

4 total filings
· daily

All NASA Contracts — April 18, 2026

NASA awarded $6,006,015 in total obligations across two contracts to Lockheed Martin Corporation from NASA Glenn Research Center, representing a 100% civilian split with 0/2 defense-related awards. The dominant theme is basic space R&D services (PSC AR11, NAICS 541715) under cost-plus-fixed-fee structures, both non-competed with no set-asides. Highest-conviction signal is neutral (avg strength 2/10, materiality 1/10), reflecting minor revenue additions for Lockheed Martin amid ongoing NASA basic research funding. Both contracts show significant outlays ($3,210,919 and $2,264,952 respectively) with options unexercised, signaling low execution risk but limited upside. Key watch item: monitor option exercises to reach $3,871,841 and $2,671,620 ceilings by performance end date of 2026-06-30.

2 total filings
· daily

Biotech Small-Cap Approvals — April 17, 2026

The FDA recorded 4 'Other' (fallback) approvals from April 13-15, 2026, categorized as 0 NMEs, 0 biosimilars, 0 label expansions, all with neutral signals. These involve small-molecule generic-style entries by MSN (GLYCEROL PHENYLBUTYRATE), APOTEX (CANAGLIFLOZIN), MICRO LABS (HYDROCHLOROTHIAZIDE), and NOVITIUM PHARMA (PIMOZIDE), spanning disparate therapeutic areas with no dominant theme. Highest-conviction signal is NOVITIUM PHARMA's PIMOZIDE approval (neutral, 5/10 strength and materiality), implying routine market entry with commercial details NOT_DISCLOSED. Key risk/watch item: Potential revenue pressure on originators from these entrants, balanced by neutral entrant upside absent peak sales or exclusivity data.

4 total filings
· daily

Orphan Drug Approvals — April 17, 2026

This period featured 1 FDA orphan drug approval: 0 NMEs, 0 biosimilars, 0 label expansions, and 1 other (fallback approval). No dominant therapeutic area theme emerged from the single approval. The highest-conviction bullish signal is Travere's Sparsentan (Filspari) label expansion, signaling portfolio strengthening in the orphan space with medium commercial materiality. Key risk/watch item is limited visibility into peak sales, exclusivity, pricing, and market position due to NOT_DISCLOSED data, warranting post-approval uptake monitoring.

1 total filings
· daily

New Drug Approvals (Original) — April 17, 2026

This period saw 4 Other approvals (0 NMEs, 0 biosimilars, 0 label expansions), all classified as fallback with neutral signals for generic/biosimilar entrants MSN (GLYCEROL PHENYLBUTYRATE), APOTEX (CANAGLIFLOZIN), MICRO LABS (HYDROCHLOROTHIAZIDE), and NOVITIUM PHARMA (PIMOZIDE). No dominant therapeutic area theme emerges, as approvals span urea cycle disorders, diabetes/CVD, hypertension, and psychiatric indications without clustering. Highest-conviction signal is the neutral approval for GLYCEROL PHENYLBUTYRATE to MSN, signaling modest market entry opportunity for the sponsor amid NOT_DISCLOSED commercial metrics. Key risk/watch item: potential revenue pressure on unspecified originators from these generic/biosimilar entries, balanced by limited materiality (5/10). Overall, routine generic pipeline activity with no high-impact biotech catalysts.

4 total filings
· daily

Federal Construction & Infrastructure Contracts — April 17, 2026

The single contract in this Federal Construction & Infrastructure stream totals $63,074,577 in obligations, entirely civilian with zero defense exposure, dominated by Department of Commerce/NIST building renovation work. Whiting-Turner Contracting Company secured this full and open competition firm fixed price award in 2020, providing multi-year revenue visibility through October 2025 but with only $3,162,695 outlayed to date amid $17,284,290 in subawards. The highest-conviction signal is neutral (5/10 strength), balancing revenue potential against execution risks. No dominant sector growth theme emerges from this isolated civilian maintenance project. Key risk is high firm fixed price execution exposure; watch outlay acceleration and option exercises toward the $78,053,862 ceiling.

1 total filings
· daily

VA Healthcare & Services Contracts — April 17, 2026

Optum Public Sector Solutions, Inc., a subsidiary of UnitedHealth Group Incorporated, secured three firm fixed price delivery orders totaling $2,779,468,829 from the Department of Veterans Affairs, representing a major civilian allocation to managed healthcare services (PSC Q201, NAICS 524114) with zero defense exposure. These awards, spanning $1.1B, $894.5M, and $782.1M obligations, signal strong bullish conviction for UnitedHealth Group's VA healthcare revenue stream via full and open competition wins. The dominant theme is VA's FY26 Q1 emphasis on short-duration (one-month) medical-managed healthcare contracts in Fredericksburg, VA. Highest-conviction bullish signal stems from the two highest-materiality awards ($1.1B and $894.5M at 8/10 materiality). A key risk is execution uncertainty, as all contracts show $0 outlayed to date, performance periods in Nov-Dec 2025 precede the 2026-04-15 award date, and high pricing risk prevails.

3 total filings
· daily

New Federal Contractors — April 17, 2026

This digest covers 9 new federal contracts totaling $3,699,283,364 in obligations, all civilian agency awards with 0 defense-related exposure. Department of Veterans Affairs dominates via three massive awards to Optum Public Sector Solutions, Inc. (subsidiary of UnitedHealth Group Incorporated) totaling $2,779,468,829 for managed healthcare services, representing ~75% of aggregate value and the highest-conviction bullish signal for UNH stock amid VA FY26 Q1 spending. GSA follows with four awards ($691,722,705 total) to Booz Allen Hamilton Inc., General Dynamics Information Technology, Inc., and Deloitte Consulting LLP in engineering and IT support. Key risk is execution uncertainty from $0 outlays across most contracts and anomalous award dates post-dating performance periods (e.g., 2026-04-15 awards for 2025 performance).

9 total filings
· daily

Significant Contract Modifications ($10M+) — April 17, 2026

This digest covers 9 significant civilian contract modifications totaling $3,699,283,364 in obligations from April 17, 2026, with 0 defense-related awards, highlighting robust civilian agency spending led by the Department of Veterans Affairs (VA) on managed healthcare via Optum Public Sector Solutions, Inc. The dominant theme is VA's allocation of ~$2.78B across three Optum awards ($1.10B, $894.5M, $782.1M), signaling strong demand for medical-managed healthcare services (NAICS 524114, PSC Q201). Highest-conviction bullish signal is on UnitedHealth Group Incorporated (Optum's parent) for these multi-hundred-million-dollar firm fixed price delivery orders under full and open competition. GSA also features prominently with awards to Booz Allen Hamilton Inc. ($492M) and General Dynamics Information Technology, Inc. ($113.5M). Key risk is execution uncertainty for Optum contracts due to award dates (2026-04-15) post-dating performance periods (e.g., 2025-11-01 to 2025-11-30) and $0 outlays to date.

9 total filings
· daily

Contract Deobligations Alert — April 17, 2026

Nine civilian agency contract deobligations alert totaling $3,699,283,364 in obligations feature dominant VA awards to Optum Public Sector Solutions, Inc. (UnitedHealth Group Incorporated subsidiary) exceeding $2.78B across three managed healthcare delivery orders, alongside GSA contracts to Booz Allen Hamilton Inc. ($492M) and General Dynamics Information Technology, Inc. ($113.5M). With 0/9 defense-related, signals emphasize civilian healthcare and IT services growth. Highest-conviction bullish signal is Optum's $1.1B VA award, reinforcing UnitedHealth Group's moat in VA managed care. Key risk is pervasive $0 outlays and performance periods predating 2026-04-15 award dates (e.g., Optum's Nov/Dec 2025 execution), signaling potential execution delays or data anomalies.

9 total filings
· daily

Contract Option Exercises — April 17, 2026

This digest covers $3,699,283,364 in 9 civilian agency contract option exercises from April 17, 2026, with 0/9 defense-related awards, highlighting a civilian-heavy stream dominated by Department of Veterans Affairs (VA) managed healthcare obligations totaling ~$2.78B to Optum Public Sector Solutions, Inc. (UnitedHealth Group subsidiary). Highest-conviction bullish signal is UnitedHealth Group's ~$2.78B VA awards across three firm-fixed-price delivery orders, signaling strong positioning in VA FY26 Q1 healthcare despite execution uncertainties. GSA awards to Booz Allen Hamilton ($492M), General Dynamics IT ($113M), and Deloitte ($86M) add multi-year IT/engineering revenue visibility with low pricing risk via cost-plus structures. Key risk is pervasive $0 outlays and anomalous award dates post-dating performance periods (e.g., 2026-04-15 awards for 2025 performance) across top Optum contracts, warranting outlay and execution monitoring. Overall average signal strength of 6.0/10 reflects bullish tilt tempered by high fixed-price risks and private firm exposure limiting direct public market impact.

9 total filings
· daily

Federal Professional Services Contracts — April 17, 2026

These three civilian federal professional services contracts total $640,383,670 in obligations, with zero defense-related awards, highlighting pure civilian exposure via GSA (two awards totaling $578.2M) and Department of the Interior ($62.2M). Dominant theme is GSA-driven engineering and program management support, led by Booz Allen Hamilton Inc.'s highest-materiality $492M bullish signal under a cost-plus award fee structure with low revenue risk through 2025. Deloitte Consulting LLP adds a $86.2M bullish multi-year stream, while JBS International, Inc. provides neutral $62.2M visibility with strong $58.3M outlays already. Highest-conviction signal is Booz Allen's competitive win demonstrating moat in GSA engineering services. Key watch item is minimal outlays across contracts (e.g., Booz Allen at -$1,508, Deloitte at $0), signaling potential delays in revenue realization amid option exercises.

3 total filings
· daily

Federal IT & Cybersecurity Contracts — April 17, 2026

Two civilian IT contracts totaling $216,356,287 in obligations highlight Federal IT services demand, with 0/2 defense-related awards split between GSA and Department of State. General Dynamics Information Technology, Inc. (General Dynamics Corp subsidiary) secured the highest-materiality $113.5 million GSA delivery order for Strategic Command IT Lifecycle Support at Offutt AFB, offering bullish long-term potential up to $1.475 billion through 2032 if options exercised. Koniag Management Solutions LLC's $102.9 million 8(a) sole-source Department of State contract for Cloud Program Management is neutral due to its private status and impending February 2025 end date. Highest-conviction signal is bullish on General Dynamics Corp from the GSA award's scale and duration. Key watch item: zero outlays across both contracts signal execution risk pending funding progress.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — April 17, 2026

This week's Mega Contracts Monitor captures $3,487,874,841 in civilian agency obligations across 6 awards, with 0/6 defense-related and a dominant theme of Department of Veterans Affairs spending on managed healthcare via three awards to Optum Public Sector Solutions, Inc. (UnitedHealth Group Incorporated subsidiary) totaling $2,779,468,829. GSA follows with engineering and IT services awards to Booz Allen Hamilton Inc. ($492M) and General Dynamics Information Technology, Inc. ($113M), while Department of State awarded Koniag Management Solutions LLC ($102M). Highest-conviction bullish signal is on UnitedHealth Group from Optum's full and open competition wins in VA medical-managed healthcare, signaling strong positioning in civilian healthcare services. Key risk is execution uncertainty from $0 outlays across most contracts and anomalous award dates (2026-04-15) preceding performance periods (e.g., 2025-11/12 for Optum awards).

6 total filings
· daily

High-Value Federal Grants ($5M+) — April 17, 2026

This digest covers 9 high-value federal grants totaling $3,699,283,364 in obligations, all civilian with 0 defense-related awards, spanning agencies like VA, GSA, State, Commerce, and Interior. Department of Veterans Affairs dominates with $2,779,468,829 (75%) awarded to Optum Public Sector Solutions, Inc. (UnitedHealth Group subsidiary) in three firm-fixed price managed healthcare delivery orders, signaling strong conviction bullish exposure for UNH in VA healthcare services. GSA follows with $691,722,705 across Booz Allen Hamilton ($492M engineering), General Dynamics IT ($113M IT lifecycle), and Deloitte ($86M program management). Key risk is widespread $0 outlays to date and award dates post-dating performance periods (e.g., Optum's 2026-04-15 awards for 2025 performance), warranting watch on execution and funding progress.

9 total filings
· daily

General Federal Contracts — April 17, 2026

These 9 civilian contracts total $3,699,283,364 in obligations with 0 defense-related awards, dominated by Department of Veterans Affairs allocations exceeding $2.78B to Optum Public Sector Solutions, Inc. (UnitedHealth Group subsidiary) for managed healthcare services. GSA follows with key awards to Booz Allen Hamilton ($492M), General Dynamics Information Technology ($113M), and Deloitte Consulting ($86M) in engineering and IT support. Highest-conviction bullish signal is UnitedHealth Group's massive VA healthcare wins signaling durable revenue in civilian healthcare. Key risk is execution uncertainty from $0 outlays across top Optum awards and performance periods (Nov-Dec 2025) predating 2026-04-15 award dates.

9 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 17, 2026

The 20 filings reveal a bifurcated S&P 500 Technology landscape: robust institutional conviction in mega-cap tech leaders (Broadcom, Apple, Nvidia topping multiple 13Fs with $3.7B+ positions) contrasts sharply with distress in micro/small-cap tech/biotech adjacents (MBIO delisting risk, Madison Tech zero revenues/losses +6.4% YoY, Acquisition Corp cash to $85). Key period trends include Tencent Music's strong consolidated revenue +15.9% YoY to RMB32.9B and profit +59.7% YoY, offset by VIE gross profit -55.5% YoY; Chemung Financial Q1 NI +53.3% YoY (tech holdings heavy); mixed SPAC swings to losses. Critical developments: MAIR IPO at $27/share (82M shares, trading Apr 16), Cumulus $600M debt cut via bankruptcy approval, C2 Blockchain insider cancels 245M shares, TI strong AGM votes (board 100% elected). Capital allocation leans conservative (Chemung $0.34 div, Evommune no divs planned); no major insider buys/sells beyond C2 reduction. Portfolio implications: overweight large-cap semis/AI (13Fs aggregate billions in AVGO/NVDA/AAPL), avoid microcaps, monitor IPOs/restructures for alpha.

7 high priority 13 medium 20 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 17, 2026

Across 20 NASDAQ-100 related filings from April 17, 2026, key themes include robust growth in entertainment/streaming (Netflix +16.2% YoY revenue, +82.8% net income; Tencent Music +15.9% revenue, +59.7% profit) contrasting with distress in smaller tech/biotech firms (Madison Technologies net loss +6.4% YoY to $2.98M, Mustang Bio Nasdaq delisting notice). Period-over-period trends show 3/5 operating companies with double-digit revenue growth (avg +16%) but mixed profitability (2/5 with widening losses), while 5/20 filings highlight capital raises/IPOs (Madison Air $27/share IPO) and restructurings (Cumulus $600M debt elimination). 13F filings (4/20) reveal concentrated exposure to mega-caps like Broadcom ($3.7B top holding), Apple, Alphabet. Proxy battles and board changes signal governance focus (TXI strong approvals, Faraday 3 resignations/3 appointments). Material events like bankruptcies, delistings, and upcoming AGMs create volatility, with positive sentiment in 4/20 (20%) vs negative in 4/20 (20%). Portfolio implications: Favor large-cap streamers over micro-caps amid proxy season catalysts.

11 high priority 9 medium 20 total filings